To assess whether the combined IFN-α and SG600-IL-24 treatment was moreeffective in suppressing cell viability, the hepatocellular carcinoma cell linesHepG2, MHCC97L, and HCCLM3, along with the normal liver cell line L02, weretreated as described, and a fifth group was treated with both IFN-α andSG600-IL-24. The gene discussed is IFNA17; the disease is hepatocellular carcinoma.